Smart Design of Small‐Molecule Libraries: When Organic Synthesis Meets Cheminformatics
暂无分享,去创建一个
[1] Yanli Wang,et al. PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..
[2] Herbert Waldmann,et al. Bioactivity-guided navigation of chemical space. , 2010, Accounts of chemical research.
[3] Fabrizio Giordanetto,et al. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? , 2014, Journal of medicinal chemistry.
[4] R. Sarpong,et al. Construction of Enantiopure Taxoid and Natural Product-like Scaffolds Using a C-C Bond Cleavage/Arylation Reaction. , 2015, Organic letters.
[5] Derek S. Tan,et al. Diversity-oriented synthesis: exploring the intersections between chemistry and biology , 2005, Nature chemical biology.
[6] David R Spring,et al. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. , 2010, Nature communications.
[7] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[8] Channa K. Hattotuwagama,et al. Lead-oriented synthesis: a new opportunity for synthetic chemistry. , 2012, Angewandte Chemie.
[9] Andrew J. Bannister,et al. A Chemical Probe for the ATAD2 Bromodomain. , 2016, Angewandte Chemie.
[10] Adam Nelson,et al. A divergent synthetic approach to diverse molecular scaffolds: assessment of lead-likeness using LLAMA, an open-access computational tool. , 2016, Chemical communications.
[11] Petra Schneider,et al. Counting on natural products for drug design. , 2016, Nature chemistry.
[12] R. Morgentin,et al. Synthesis of sp(3)-rich scaffolds for molecular libraries through complexity-generating cascade reactions. , 2016, Organic & biomolecular chemistry.
[13] Adam Nelson,et al. Evaluating New Chemistry to Drive Molecular Discovery: Fit for Purpose? , 2016, Angewandte Chemie.
[14] Jürgen Bajorath,et al. Application of a New Scaffold Concept for Computational Target Deconvolution of Chemical Cancer Cell Line Screens , 2017, ACS omega.
[15] David DeCaprio,et al. Cheminformatics approaches to analyze diversity in compound screening libraries. , 2010, Current opinion in chemical biology.
[16] J. Christoffers,et al. Quaternary Stereocenters: Challenges and Solutions for Organic Synthesis , 2005 .
[17] H. Waldmann,et al. Discovery of inhibitors of the Wnt and Hedgehog signaling pathways through the catalytic enantioselective synthesis of an iridoid-inspired compound collection. , 2013, Angewandte Chemie.
[18] A. Hopkins,et al. Navigating chemical space for biology and medicine , 2004, Nature.
[19] Jürgen Bajorath,et al. Analog series-based scaffolds: computational design and exploration of a new type of molecular scaffolds for medicinal chemistry , 2016, Future science OA.
[20] S. Knapp,et al. Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies. , 2017, Journal of medicinal chemistry.
[21] A. Trabocchi,et al. Diversity-Oriented Synthesis and Chemoinformatic Analysis of the Molecular Diversity of sp3-Rich Morpholine Peptidomimetics , 2018, Front. Chem..
[22] A. H. Lipkus,et al. Structural Diversity of Organic Chemistry. a Scaffold Analysis of the Cas Registry , 2022 .
[23] Stuart L. Schreiber,et al. A small molecule that binds Hedgehog and blocks its signaling in human cells , 2009, Nature chemical biology.
[24] S. Wetzel,et al. Biologie‐orientierte Synthese (BIOS) , 2011 .
[25] Suresh B. Singh,et al. The use of spirocyclic scaffolds in drug discovery. , 2014, Bioorganic & medicinal chemistry letters.
[26] R. Hicklin,et al. Synthesis of complex and diverse compounds through ring distortion of abietic acid. , 2014, Angewandte Chemie.
[27] Andrei K. Yudin,et al. Macrocycles: lessons from the distant past, recent developments, and future directions , 2014, Chemical science.
[28] José L Medina-Franco,et al. Molecular Scaffold Analysis of Natural Products Databases in the Public Domain , 2012, Chemical biology & drug design.
[29] Markus Hartenfeller,et al. A Collection of Robust Organic Synthesis Reactions for In Silico Molecule Design , 2011, J. Chem. Inf. Model..
[30] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[31] H. Waldmann,et al. A natural product inspired tetrahydropyran collection yields mitosis modulators that synergistically target CSE1L and tubulin. , 2013, Angewandte Chemie.
[32] Oliver Koch,et al. What Can We Learn from Bioactivity Data? Chemoinformatics Tools and Applications in Chemical Biology Research. , 2017, ACS chemical biology.
[33] Jeremy L. Jenkins,et al. Clustering and Rule-Based Classifications of Chemical Structures Evaluated in the Biological Activity Space , 2007, J. Chem. Inf. Model..
[34] Santiago Vilar,et al. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. , 2008, Current topics in medicinal chemistry.
[35] K. Lam,et al. Combinatorial chemistry in drug discovery. , 2017, Current opinion in chemical biology.
[36] Karina Martinez-Mayorga,et al. Balancing novelty with confined chemical space in modern drug discovery , 2014, Expert opinion on drug discovery.
[37] A. Trabocchi,et al. Diversity-Oriented Synthesis as a Tool for Chemical Genetics , 2014, Molecules.
[38] A. Alexakis,et al. Metal-catalyzed asymmetric conjugate addition reaction: formation of quaternary stereocenters. , 2010, Chemical communications.
[39] R. Hicklin,et al. A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. , 2013, Nature chemistry.
[40] A. Trabocchi,et al. Diversity-oriented synthesis of morpholine-containing molecular scaffolds. , 2009, Chemistry.
[41] C. Vanderwal,et al. Efficient access to the core of the Strychnos, Aspidosperma and Iboga alkaloids. A short synthesis of norfluorocurarine. , 2009, Journal of the American Chemical Society.
[42] Adam Nelson,et al. Synthesis and Demonstration of the Biological Relevance of sp3‐rich Scaffolds Distantly Related to Natural Product Frameworks , 2017, Chemistry.
[43] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.
[44] Thomas Kodadek,et al. Quantitative comparison of the relative cell permeability of cyclic and linear peptides. , 2007, Chemistry & biology.
[45] Stefan Wetzel,et al. Interactive exploration of chemical space with Scaffold Hunter. , 2009, Nature chemical biology.
[46] Peter Ertl,et al. The graphical representation of ADME-related molecule properties for medicinal chemists. , 2011, Drug discovery today.
[47] Stuart L. Schreiber,et al. Chemical probes and drug leads from advances in synthetic planning and methodology , 2018, Nature Reviews Drug Discovery.
[48] C. Swain,et al. Spirocyclic NK(1) antagonists I: [4.5] and [5.5]-spiroketals. , 2002, Bioorganic & medicinal chemistry letters.
[49] Andreas Bender,et al. How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space , 2009, J. Chem. Inf. Model..
[50] Matthew P Jacobson,et al. Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.
[51] Russ B Altman,et al. Machine learning in chemoinformatics and drug discovery. , 2018, Drug discovery today.
[52] Daniel J. Foley,et al. Evaluierung neuer Reaktionen zur Steuerung der Wirkstoff-Forschung: ein Eignungstest , 2016 .
[53] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[54] H. Maehr. Combinatorial chemistry in drug research from a new vantage point. , 1997, Bioorganic & medicinal chemistry.
[55] David R Spring,et al. Diversity-oriented synthesis: producing chemical tools for dissecting biology. , 2012, Chemical Society reviews.
[56] Gisbert Schneider,et al. Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.
[57] Prasanna Venkatraman. Specificity in the interaction of natural products with their target proteins--a biochemical and structural insight. , 2010, Mini reviews in medicinal chemistry.
[58] Sorel Muresan,et al. ChemGPS-NP: tuned for navigation in biologically relevant chemical space. , 2006, Journal of natural products.
[59] Stephen J Haggarty,et al. Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β. , 2016, ACS medicinal chemistry letters.
[60] W. Unsworth,et al. Ring-Expansion Approach to Medium-Sized Lactams and Analysis of Their Medicinal Lead-Like Properties. , 2017, Chemistry.
[61] S. Schreiber,et al. Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.
[62] Ross McGuire,et al. Data-driven medicinal chemistry in the era of big data. , 2014, Drug discovery today.
[63] Tudor I. Oprea,et al. Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..
[64] Wolfgang H. B. Sauer,et al. Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity , 2003, J. Chem. Inf. Comput. Sci..
[65] Stefan Wetzel,et al. Cheminformatic Analysis of Natural Products and their Chemical Space , 2007 .
[66] G. Müller,et al. Medicinal chemistry of target family-directed masterkeys. , 2003, Drug discovery today.
[67] Xu-dong Cao,et al. Design and diversity-oriented synthesis of novel 1,4-thiazepan-3-ones fused with bioactive heterocyclic skeletons and evaluation of their antioxidant and cytotoxic activities. , 2012, Bioorganic & medicinal chemistry letters.
[68] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[69] Stephen P. Hale,et al. The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.
[70] B. B. Mishra,et al. Natural products: an evolving role in future drug discovery. , 2011, European journal of medicinal chemistry.
[71] E. Barreiro,et al. From nature to drug discovery: the indole scaffold as a 'privileged structure'. , 2009, Mini reviews in medicinal chemistry.
[72] Hong-min Liu,et al. Spirooxindoles: Promising scaffolds for anticancer agents. , 2015, European journal of medicinal chemistry.
[73] Stefan Wetzel,et al. Biology-oriented synthesis. , 2011, Angewandte Chemie.
[74] D Rognan,et al. Towards the Next Generation of Computational Chemogenomics Tools , 2013, Molecular informatics.
[75] M. Hann. Molecular obesity, potency and other addictions in drug discovery , 2011 .
[76] J. Sánchez-Quesada,et al. Design and Synthesis of Fsp(3)-Rich, Bis-Spirocyclic-Based Compound Libraries for Biological Screening. , 2016, ACS combinatorial science.
[77] Christopher J. White,et al. Contemporary strategies for peptide macrocyclization. , 2011, Nature chemistry.
[78] C. Lipinski. Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.
[79] Stefan Wetzel,et al. Charting, navigating, and populating natural product chemical space for drug discovery. , 2012, Journal of medicinal chemistry.
[80] E. Furfine,et al. New, potent P1/P2-morpholinone-based HIV-protease inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[81] Stuart L. Schreiber,et al. Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles , 2010, Proceedings of the National Academy of Sciences.
[82] W Patrick Walters,et al. What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.
[83] J. Bajorath,et al. Charting Biologically Relevant Spirocyclic Compound Space. , 2017, Chemistry.
[84] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[85] Petra Schneider,et al. Chemography of Natural Product Space , 2015, Planta Medica.
[86] Herbert Waldmann,et al. Biology-oriented synthesis: harnessing the power of evolution. , 2014, Journal of the American Chemical Society.
[87] Gisbert Schneider,et al. Nonlinear dimensionality reduction and mapping of compound libraries for drug discovery. , 2012, Journal of molecular graphics & modelling.
[88] A. Nadin,et al. Leitstruktur‐orientierte Synthese: eine Alternative für die Synthesechemie , 2012 .
[89] Elisabet Gregori-Puigjané,et al. Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors. , 2016, Journal of medicinal chemistry.
[90] R. Sarpong,et al. Selective C-C and C-H bond activation/cleavage of pinene derivatives: synthesis of enantiopure cyclohexenone scaffolds and mechanistic insights. , 2015, Journal of the American Chemical Society.
[91] Emanuele Perola,et al. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.
[92] A. Trabocchi,et al. Two-step one-pot synthesis of dihydropyrazinones as Xaa-Ser dipeptide isosteres through morpholine acetal rearrangement. , 2015, Organic & biomolecular chemistry.
[93] É. Marsault,et al. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. , 2011, Journal of medicinal chemistry.
[94] Zoya Titarenko,et al. BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery , 2010, Molecular Diversity.
[95] A. Trabocchi,et al. Short synthesis of polyfunctional sp3-rich threonine-derived morpholine scaffolds. , 2017, Organic & biomolecular chemistry.